Swedish fertility diagnostics company Spermosens AB (Spotlight Stock Market: SPERM) said on Monday it has signed a collaboration framework agreement with Australian fertility group Genea Pty Ltd to support an independent clinical study of its JUNO-Checked diagnostic in IVF cycles, subject to ethics approval and a separate study agreement.

The prospective observational study will be conducted at one or more Genea clinics in Australia and will assess whether JUNO-Checked results are associated with fertilisation outcomes in IVF patients who consent to participate. Test results will not be used to guide treatment decisions during the study.

Genea will provide clinical laboratory staff, IVF infrastructure and research governance, including ethics approval, while Spermosens will supply the JUNO-Checked instrumentation, sensors and software. Each party will bear its own costs, with commercial terms to be negotiated after study milestones are achieved.

Spermosens said the agreement expands its clinical programme beyond Sweden into an international market, and marks the first evaluation of JUNO-Checked by an external clinic group.

The study is expected to begin following Human Research Ethics Committee approval, anticipated in mid-2027, however, timing and outcomes remain dependent on several factors and cannot be guaranteed.